Targanta Revives Oritavancin: Next Weapon Against cSSSI?

Remember FDA-stalled oritavancin? The hospital-based glycopeptide antibiotic acquired in 2001 by InterMune Inc. from Eli Lilly and Co. (which developed the compound as a replacement for vancomycin, which still takes an estimated 80 percent share of the market) was bought by Targanta Therapeutics Inc around Christmas four years later. (BioWorld Financial Watch)